How to Monitor Iloperidone Safety During Acute Bipolar Mania Treatment
How should clinicians monitor safety during the first month of iloperidone treatment for acute bipolar mania?
When iloperidone is chosen for acute bipolar mania, early tolerability can determine whether a patient can stay on treatment long enough to benefit. This guide focuses on the specific adverse effects and monitoring domains highlighted in the 28-day bipolar mania trial.
-
Monitor most closely during the titration period
The study found that orthostatic responses were more frequent during titration and then declined to placebo-like rates after day 10. Build the closest follow-up into the first several days of treatment, when autonomic effects were most prominent.
-
Check orthostatic vital signs
The trial defined orthostatic response as a fall of 20 mm Hg or more in systolic blood pressure and or 10 mm Hg or more in diastolic blood pressure. Orthostatic response was higher with iloperidone during titration but was low later, with rates at week 4 of 5.6% on iloperidone and 4.5% on placebo.
-
Obtain ECG-based cardiac monitoring and review QTc risk
QTcF increased by a mean of 8.3 msec from baseline to day 28 with iloperidone, compared with a mean change of -1.0 msec with placebo. Post-randomization QTcF increases of 60 msec or more occurred in 3 iloperidone-treated patients and 0 placebo-treated patients, so ECG follow-up is clinically relevant.
-
Account for CYP2D6 metabolism and avoid interacting metabolic inhibitors
The discussion states that QTc increases can be managed in practice by following prescribing directions to avoid contraindicated metabolic inhibitors and by reducing dosage by half in patients with impaired CYP2D6 metabolism. In the trial, CYP2D6 poor metabolizers received 12 mg/day rather than 24 mg/day.
-
Track pulse and ask about autonomic symptoms
Tachycardia was the most common adverse event, occurring in 17.5% of iloperidone-treated patients. The average increase in ventricular rate was slightly higher during titration and was still 4.7 beats per minute above baseline at week 4, compared with 1.5 beats per minute on placebo.
-
Follow weight and metabolic laboratory signals
Mean weight gain over 28 days was 4.60 kg with iloperidone versus 1.63 kg with placebo. Mild to moderate increases in alanine aminotransferase and prolactin were observed in some iloperidone-treated patients, while no major difference was seen in mean fasting glucose over the 28-day study.
-
Assess for akathisia and extrapyramidal symptoms
Akathisia was reported as an adverse event in 4.4% of iloperidone-treated patients and in no placebo-treated patients, but no patient discontinued because of akathisia. Rates of extrapyramidal symptoms were otherwise low and similar to placebo, with no statistically significant between-group differences on BARS, SAS, or AIMS change scores.
-
Watch for adverse events that may lead to stopping treatment
At least 1 adverse event occurred in 67.5% of iloperidone-treated patients, and 8.7% discontinued study drug because of treatment-emergent adverse events. Common adverse events occurring in more than 5% of iloperidone-treated patients were tachycardia, dizziness, dry mouth, alanine aminotransferase increased, nasal congestion, increased weight, and somnolence.
Clinical Considerations
- These monitoring observations come from a 28-day trial and do not establish long-term safety during maintenance treatment of bipolar disorder.
- All patients were hospitalized in the study, which may have improved detection of orthostasis, ECG changes, and adherence compared with routine outpatient care.
- The trial excluded patients with significant ECG abnormalities and other major comorbidities, so the observed safety profile may not extend to higher-risk populations.
Bottom Line
When using iloperidone for acute bipolar mania, monitor most intensively early in treatment for orthostatic effects and cardiac changes, while also tracking tachycardia, weight gain, liver and prolactin changes, and akathisia or other extrapyramidal symptoms.
